Acute myeloid leukemia (AML) is a highly aggressive illness distinguished by the
accumulation of abnormal hematopoietic precursors in both the bone marrow and peripheral …

The emergence of the precision medicine paradigm in oncology has led to increasing
interest in the integration of real-world data (RWD) into cancer clinical research. As sources …

This is the primary report of the randomized, placebo-controlled phase 3 BRIGHT AML 1019
clinical trial of glasdegib in combination with intensive chemotherapy (cytarabine and …

Engineering immune cells to treat hematological malignancies has been a major focus of
research since the first resounding successes of CAR-T-cell therapies in B-ALL. Several …

Geriatría, 5a ed. está dedicada para que los estudiantes de la licenciatura de medicina
tengan nociones básicas sobre la geriatría, a los médicos generales para que no se olviden …

Subtyping of acute myeloid leukaemia (AML) is predominantly based on recurrent genetic
abnormalities, but recent literature indicates that transcriptomic phenotyping holds immense …

This study aimed to validate the new European Leukemia Net (ELN) 2022 criteria for genetic
risk stratification in older adults with acute myeloid leukemia (AML) and to determine the …

Background Our study examined the global, national, and regional trends in the incidence,
mortality, and disability-adjusted life years (DALYs) associated with older people's acute …

Simple Summary Measurable residual disease (MRD) is emerging as an important
prognostic and predictive biomarker in acute myeloid leukemia (AML). However, its use is …

Objective Acute myeloid leukaemia (AML) prognosis is enhanced with intensive remission
induction chemotherapy (ICT) in eligible patients. However, ICT eligibility perceptions may …